IMPAACT Studies in Development

The study you are looking for is in protocol development.

As the study protocol reaches Version 1.0, a study page will be developed.

  Study Number
(DAIDS ID)
Study Title Status

IMPAACT 2023

(TBD)

A Phase I Trial to Evaluate the Safety and Pharmacokinetics of Dolutegravir in HIV-1 Exposed Neonates at Risk of Acquiring HIV-1 Infection

In Development

IMPAACT 2022

(38631)

Phase II Study of the Virologic Efficacy and Feasibility of Long-Acting Injectable Antiretroviral Medications in Non-Adherent Youth with HIV

In Development

IMPAACT 2026

(TBD)

Pharmacokinetic Properties of Antiretroviral, Anti-Tuberculosis, Contraceptive and Related Drugs During Pregnancy and Postpartum

In Development

IMPAACT 2021

(38530)

Randomized Phase I/II Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/delta 1313/I1314L, RSV delta 6120/NS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

In Development

IMPAACT 2020

(38505)

Shortened Oral Treatment for Multidrug-Resistant Tuberculosis in Infants, Children and Adolescents (SMaRT Kids): A Phase III Randomized Multi-center Trial

In Development


Return to the full list of studies

 

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.